Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

PURPOSE: Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of diffuse large B-cell lymphoma (DLBCL). The impact of baseline organ function–based eligibility criteria on this effect...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Khurana, Arushi, Mwangi, Raphael, Nowakowski, Grzegorz S., Habermann, Thomas M., Ansell, Stephen M., LaPlant, Betsy R., Link, Brian K., Cerhan, James R., Maurer, Matthew J., Witzig, Thomas E.
Формат: Artigo
Язык:Inglês
Опубликовано: Wolters Kluwer Health 2021
Предметы:
ORIGINAL REPORTS
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8274741/
https://ncbi.nlm.nih.gov/pubmed/33529046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01935
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы